Lam Research (LRCX) came out with quarterly earnings of $1.33 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $0.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +10.83%. A quarter ago, it was expected that this semiconductor equipment maker would post earnings of $1 per share when it actually produced earnings of $1.04, delivering a surprise of +4%.Over the last four quarters, ...

Udemy, Inc. (UDMY) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this company would post earnings of $0.1 per share when it actually produced earnings of $0.12, delivering a surprise of +20%.Over the last four quarters, the company has surp ...

分组1 - DexCom reported quarterly earnings of $0.48 per share, exceeding the Zacks Consensus Estimate of $0.45 per share, and showing an increase from $0.43 per share a year ago, representing an earnings surprise of +6.67% [1] - The company achieved revenues of $1.16 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.06%, and up from $1 billion in the same quarter last year [2] - DexCom has outperformed the S&P 500 with a stock increase of about 14.9% since the beginning of the year, compared to the S&P 500's gain of 8.3% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.57 on revenues of $1.18 billion, and for the current fiscal year, it is $2.03 on revenues of $4.61 billion [7] - The Zacks Industry Rank indicates that the Medical - Instruments sector is currently in the bottom 35% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - DexCom holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6]

Core Insights - Magnolia Oil & Gas Corp reported quarterly earnings of $0.43 per share, exceeding the Zacks Consensus Estimate of $0.40 per share, but down from $0.56 per share a year ago, representing an earnings surprise of +7.50% [1] - The company achieved revenues of $318.98 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.67%, although this is a decrease from $336.73 million in the same quarter last year [2] - Magnolia Oil & Gas has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.44, with expected revenues of $320.01 million, and for the current fiscal year, the EPS estimate is $1.83 on revenues of $1.31 billion [7] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Context - The Oil and Gas - Exploration and Production - United States industry is currently ranked in the bottom 31% of over 250 Zacks industries, suggesting potential challenges for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Neurocrine Biosciences reported quarterly earnings of $1.06 per share, exceeding the Zacks Consensus Estimate of $0.98 per share, and showing a significant increase from $0.63 per share a year ago, indicating strong performance in the biopharmaceutical sector [1][2] Financial Performance - The company achieved revenues of $687.5 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.72% and reflecting a year-over-year increase from $590.2 million [2] - Over the last four quarters, Neurocrine has exceeded consensus revenue estimates three times, showcasing its ability to perform well in a competitive market [2] Stock Performance and Outlook - Neurocrine shares have declined approximately 1.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.3%, indicating underperformance relative to the broader market [3] - The current consensus EPS estimate for the upcoming quarter is $1.31 on revenues of $705.5 million, while for the current fiscal year, the estimate is $3.77 on revenues of $2.66 billion [7] Industry Context - The Medical - Drugs industry, to which Neurocrine belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable environment for companies within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Neurocrine's stock performance [5][6]

Core Insights - Wingstop (WING) reported quarterly earnings of $1 per share, exceeding the Zacks Consensus Estimate of $0.88 per share, and showing an increase from $0.93 per share a year ago, resulting in an earnings surprise of +13.64% [1] - The company posted revenues of $174.33 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.05%, but up from $155.7 million year-over-year [2] - Wingstop has surpassed consensus EPS estimates three times over the last four quarters and topped revenue estimates twice in the same period [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.97 on revenues of $189.28 million, while the estimate for the current fiscal year is $3.91 on revenues of $731 million [7] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Retail - Restaurants industry, to which Wingstop belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Wingstop's stock performance [5]

Core Viewpoint - AerCap reported quarterly earnings of $2.83 per share, exceeding the Zacks Consensus Estimate of $2.75 per share, but down from $3.01 per share a year ago, indicating a +2.91% earnings surprise [1] - The company generated revenues of $1.89 billion for the quarter, missing the Zacks Consensus Estimate by 5.72% and down from $1.96 billion year-over-year [2] Group 1: Earnings Performance - AerCap has surpassed consensus EPS estimates three times over the last four quarters [2] - The company had a significant earnings surprise of +36.8% in the previous quarter, where it reported earnings of $3.68 per share against an expectation of $2.69 [1] Group 2: Revenue Insights - The revenue of $1.89 billion for the latest quarter reflects a decline from the previous year's $1.96 billion [2] - The company has also topped consensus revenue estimates three times in the last four quarters [2] Group 3: Stock Performance and Outlook - AerCap shares have increased by approximately 17.7% since the beginning of the year, outperforming the S&P 500's gain of 8.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 4: Future Earnings Expectations - The current consensus EPS estimate for the upcoming quarter is $2.83 on revenues of $2.01 billion, and for the current fiscal year, it is $12.42 on revenues of $8.16 billion [7] - The outlook for the industry, particularly the Transportation - Equipment and Leasing sector, is favorable, ranking in the top 37% of Zacks industries [8]

Core Viewpoint - Tradeweb Markets reported quarterly earnings of $0.87 per share, exceeding the Zacks Consensus Estimate of $0.86 per share, and showing an increase from $0.70 per share a year ago, indicating a positive earnings surprise of +1.16% [1][2] Financial Performance - The company achieved revenues of $512.97 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.53%, and up from $404.95 million year-over-year [2] - Over the last four quarters, Tradeweb has exceeded consensus EPS estimates three times and has also topped consensus revenue estimates three times [2] Stock Performance - Tradeweb shares have increased approximately 5.6% since the beginning of the year, while the S&P 500 has gained 8.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.86 on revenues of $511.33 million, and for the current fiscal year, it is $3.43 on revenues of $2.05 billion [7] - The trend of estimate revisions for Tradeweb was mixed ahead of the earnings release, which may change following the recent report [6] Industry Context - The Financial - Investment Bank industry, to which Tradeweb belongs, is currently ranked in the top 6% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - Bausch + Lomb reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, but down from $0.13 per share a year ago, representing an earnings surprise of +16.67% [1] - The company posted revenues of $1.28 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.37% and up from $1.22 billion year-over-year [2] - Over the last four quarters, Bausch + Lomb has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - Bausch + Lomb shares have declined approximately 18.9% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The current Zacks Rank for Bausch + Lomb is 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.19 on revenues of $1.27 billion, and for the current fiscal year, it is $0.47 on revenues of $5.03 billion [7] - The outlook for the Medical Services industry, where Bausch + Lomb operates, is currently in the top 37% of over 250 Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]

Company Performance - Silgan Holdings reported quarterly earnings of $1.01 per share, missing the Zacks Consensus Estimate of $1.03 per share, but showing an increase from $0.88 per share a year ago, representing an earnings surprise of -1.94% [1] - The company posted revenues of $1.54 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.31%, and an increase from $1.38 billion year-over-year [2] - Over the last four quarters, Silgan has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Future Outlook - The current consensus EPS estimate for the coming quarter is $1.36 on revenues of $1.93 billion, and for the current fiscal year, it is $4.08 on revenues of $6.44 billion [7] - The estimate revisions trend for Silgan was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - Silgan belongs to the Zacks Containers - Metal and Glass industry, which is currently in the top 16% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Silgan's stock performance [5]